FDA Accepts Supplemental NDA for Travere's Filspari (Sparsentan)
The FDA has accepted a supplemental NDA for Filspari (Sparsentan) from Travere.
Published: July 26, 2026
Updated: July 26, 2026
Author: Humanexa Intelligence
Therapeutic area: Nephrology / Drug
Company: Travere Therapeutics
Asset: FDA
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Company
Travere Therapeutics
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's acceptance of the supplemental NDA for Filspari positions Travere favorably in the nephrology market, potentially impacting competitive dynamics. Pharma strategy teams should prepare for shifts in market positioning and competitive responses as the review progresses.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor the timeline for FDA review and any upcoming data releases related to Sparsentan.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.